Tevogen Bio Holdings Past Earnings Performance
Past criteria checks 0/6
Tevogen Bio Holdings has been growing earnings at an average annual rate of 14.5%, while the Biotechs industry saw earnings growing at 7.7% annually.
Key information
14.5%
Earnings growth rate
11.4%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Tevogen Bio Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -4 | 18 | 28 |
| 30 Jun 24 | 0 | -2 | 16 | 26 |
| 31 Mar 24 | 0 | -19 | 13 | 23 |
| 31 Dec 23 | 0 | -60 | 5 | 4 |
| 30 Sep 23 | 0 | -63 | 5 | 5 |
| 30 Jun 23 | 0 | -64 | 6 | 5 |
| 31 Mar 23 | 0 | -47 | 7 | 6 |
| 31 Dec 22 | 0 | -22 | 8 | 5 |
Quality Earnings: G28 is currently unprofitable.
Growing Profit Margin: G28 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if G28's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare G28's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: G28 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: G28's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.